Colorectal Cancer Diagnostics Market (By Test Type: Blood Test, Stool Test, Fecal Occult Blood Test, Fecal Biomarker Test, CRC DNA Screening Test, Imaging Test, Computed Tomography scan, Ultrasound, Magnetic Resonance Imaging scan, Positron Emission Tomography scan, Colonoscopy, Other Imaging Tests, Biopsy, Other Test Types; By End-use: Hospitals, Diagnostic Imaging Centers, Cancer Research Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Colorectal Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Colorectal Cancer Diagnostics Market, by Test Type, 2024-2033
8.1.1. Blood Test
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Stool Test
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Fecal Occult Blood Test (FOBT)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Fecal Biomarker Test
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. CRC DNA Screening Test
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Imaging Test
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Computed Tomography (CT) scan
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Ultrasound
8.1.8.1. Market Revenue and Forecast (2021-2033)
8.1.9. Magnetic Resonance Imaging (PET) scan
8.1.9.1. Market Revenue and Forecast (2021-2033)
8.1.10. Positron Emission Tomography (PET) scan
8.1.10.1. Market Revenue and Forecast (2021-2033)
8.1.11. Colonoscopy
8.1.11.1. Market Revenue and Forecast (2021-2033)
8.1.12. Other Imaging Tests
8.1.12.1. Market Revenue and Forecast (2021-2033)
8.1.13. Biopsy
8.1.13.1. Market Revenue and Forecast (2021-2033)
8.1.14. Other Test Types
8.1.14.1. Market Revenue and Forecast (2021-2033)
9.1. Colorectal Cancer Diagnostics Market, by End-use, 2024-2033
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Diagnostic Imaging Centers
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Cancer Research Centers
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End-use (2021-2033)
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. BioMerieux SA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Dickinson and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GE Healthcare
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Qiagen N.V
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Thermo Fischer Scientific
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hologic Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Epigenomics AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. F-Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Siemens Healthineers
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample